Tandem repeats of the extracellular domain of Matrix 2 influenza protein exposed in Brucella lumazine synthase decameric carrier molecule induce protection in mice

Vaccine

Volumn 31, Issue 5, 2013, Pages 806-812

  Alvarez, Paula ^a   Zylberman, Vanesa ^a,b   Ghersi, Giselle ^a,b   Boado, Lorena ^a   Palacios, Carlos ^a   Goldbaum, Fernando ^a,b   Mattion, Nora ^a  

^a CONICET ^*  (Argentina)

^b Gral San Martín   (Argentina)

Author keywords

Brucella lumazine synthase; Chimeric subunits; Influenza A; Matrix 2 protein

Indexed keywords

BRUCELLA ABORTUS LUMAZINE SYNTHASE; DRUG CARRIER; INFLUENZA VACCINE; MATRIX 2E PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRUCELLA ABORTUS; CHIMERA; CIRCULAR DICHROISM; CONTROLLED STUDY; ESCHERICHIA COLI; FEMALE; GEL PERMEATION CHROMATOGRAPHY; HUMORAL IMMUNITY; IMMUNIZATION; INFECTION PREVENTION; INFLUENZA A; INFLUENZA VACCINATION; LIGHT SCATTERING; MOUSE; NONHUMAN; PRIORITY JOURNAL; TANDEM REPEAT;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; BRUCELLA; DRUG CARRIERS; FEMALE; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; MULTIENZYME COMPLEXES; ORTHOMYXOVIRIDAE INFECTIONS; RECOMBINANT FUSION PROTEINS; REPETITIVE SEQUENCES, AMINO ACID; SURVIVAL ANALYSIS; VACCINES, SYNTHETIC; VIRAL MATRIX PROTEINS;

EID: 84872619128     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.11.072     Document Type: Article

References (39)

1. de Wit E., Fouchier R.A. Emerging influenza. J Clin Virol 2008, 41(1):1-6.
2. Smith G.J., Vijaykrishna D., Bahl J., Lycett S.J., Worobey M., Pybus O.G., et al. Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. Nature 2009, 459:1122-1125.
3. Tite J.P., Hughes-Jenkins C., O'Callaghan D., Dougan G., Russell S.M., Gao X.M., et al. Anti-viral immunity induced by recombinant nucleoprotein of influenza A virus: II. Protection from influenza infection and mechanism of protection. Immunology 1990, 71(2):202-207.
4. Epstein S.L., Kong W.P., Misplon J.A., Lo C.Y., Tumpey T.M., Xu L., et al. Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 2005, 23:5404-5410.
5. De Filette M., Min Jou W., Birkett A., Lyons K., Schultz B., Tonkyro A., et al. Universal influenza A vaccine: optimization of M2-based constructs. Virology 2005, 337:149-161.
6. Sui J., Hwang W.C., Perez S., Wei G., Aird D., Chen L., et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 2009, 16(3):265-273.
7. Ekiert D.C., Bhabha G., Elsliger M-A., Friesen R.H., Jongeneelen M., Throsby M., et al. Antibody recognition of a highly conserved influenza virus epitope. Science 2009, 324:246-251.
8. Steel J., Lowen A.C., Wang T.T., Yondola M., Gao Q., Haye K., et al. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. mBio 2010, 1(May (1)). PII: e00018-10.
9. Zebedee S.L., Lamb R.A. Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions. Virology 1988, 62:2762-2772.
10. Sugrue R., Hay A.J. Structural characteristics of the M2 protein of influenza A viruses: evidence that it forms a tetrameric channel. Virology 1991, 180:617-624.
11. Bui M., Whittaker G., Helenius A. Effect of M1 protein and low pH on nuclear transport of influenza virus ribonucleoproteins. J Virol 1996, 70:8391-8401.
12. Sakaguchi T., Leser G.P., Lamb R.A. The ion channel activity of the influenza virus M2 protein affects transport through the Golgi apparatus. J Cell Biol 1996, 133:733-747.
13. Neirynck S., Deroo T., Saelens X., Vanlandschoot P., Jou W.M., Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 1999, 5(10):1158-1163.
14. Mozdzanowska K., Feng J., Eid M., Kragol G., Cudic M., Otvos L., et al. Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2. Vaccine 2003, 21:2616-2626.
15. Treanor J.J., Tierney E.L., Zebedee S.L., Lamb R.A., Murphy B.R. Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice. J Virol 1990, 64(3):1375-1377.
16. Liu W., Peng Z., Liu Z., Lu Y., Ding J., Chen Y.-H. High epitope density in a single recombinant protein molecule of the extracellular domain of influenza A virus M2 protein significantly enhances protective immunity. Vaccine 2004, 23:366-371.
17. De Filette M., Ramne A., Birkett A., Lycke N., Löwenadler B., Min Jou W., et al. The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection. Vaccine 2006, 24(5):544-551.
18. Ionescu R.M., Przysiecki C.T., Liang X., Garsky V.M., Fan J., Wang B., et al. Pharmaceutical and immunological evaluation of human papillomavirus virus like particle as an antigen carrier. J Pharm Sci 2006, 95:70-79.
19. Tompkins S.M., Zhao Z.S., Lo C.Y., Misplon J.A., Liu T., Ye Z., et al. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg Infect Dis 2007, 13(3):426-435.
20. Fu T.M., Grimm K.M., Citron M.P., Freed D.C., Fan J., Keller P.M., et al. Comparative immunogenicity evaluations of influenza A virus M2 peptide as recombinant virus like particle or conjugate vaccines in mice and monkeys. Vaccine 2009, 27:1440-1447.
21. Huleatt J.W., Nakaar V., Desai P., Huang Y., Hewitt D., Jacobs A., et al. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 2008, 26:201-214.
22. Fan J., Liang X., Horton M.S., Perry H.C., Citron M.P., Heidecker G.J., et al. Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine 2004, 22:2993-3003.
23. Mozdzanowska K., Zharikova D., Cudic M., Otvos L., Gerhard W. Roles of adjuvant and route of vaccination in antibody response and protection engendered by a synthetic matrix protein 2-based influenza A virus vaccine in the mouse. Virol J 2007, 4:118.
24. Velikovsky C.A., Cassataro J., Giambartolomei G.H., Goldbaum F.A., Estein S., Bowden R.A., et al. A DNA vaccine encoding lumazine synthase from Brucella abortus induces protective immunity in BALB/c mice. Infect Immun 2002, 70(5):2507-2511.
25. Velikovsky C.A., Goldbaum F.A., Cassataro J., Estein S., Bowden R.A., Bruno L., et al. Brucella lumazine synthase elicits a mixed Th1-Th2 immune response and reduces infection in mice challenged with Brucella abortus 544 independently of the adjuvant formulation used. Infect Immun 2003, 71(10):5750-5755.
26. Laplagne D.A., Zylberman V., Ainciart N., Steward M.W., Sciutto E., Fossati C.A., et al. Engineering of a polymeric bacterial protein as a scaffold for the multiple display of peptides. Proteins 2004, 57(4):820-828.
27. Zylberman V., Craig P.O., Klinke S., Braden B.C., Cauerhff A., Goldbaum F.A. High order quaternary arrangement confers increased structural stability to Brucella sp. lumazine synthase. J Biol Chem 2004, 279:8093-8101.
28. Goldbaum F.A., Velikovsky C.A., Baldi P.C., Mortl S., Bacher A., Fossati C.A. The 18-kDa cytoplasmic protein of Brucella species - an antigen useful for diagnosis - is a lumazine synthase. J Med Microbiol 1999, 48(9):833-839.
29. Goldbaum F.A., Leoni J., Wallach J.C., Fossati C.A. Characterization of an 18-kilodalton Brucella cytoplasmic protein which appears to be a serological marker of active infection of both human and bovine brucellosis. J Clin Microbiol 1993, 31(8):2141-2145.
30. Craig P.O., Alzogaray V., Goldbaum F.A. Polymeric display of proteins through high affinity leucine zipper peptide adaptors. Biomacromolecules 2012, 13(4):1112-1121.
31. Turley C.B., Rupp R.E., Johnson C., Taylor D.N., Wolfson J., Tussey L., et al. Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults. Vaccine 2011, 29(32):5145-5152.
32. El Bakkouri K., Descamps F., De Filette M., Smet A., Festjens E., Birkett A., et al. Universal vaccine based on ectodomain of Matrix Protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J Immunol 2011, 186:1022-1031.
33. ® adjuvant for antigen delivery. Adv Drug Deliv Rev 2005, 57(3):465-474.
34. ® vaccines: safety in human clinical studies. Hum Vaccine 2010, 30(6). [Epub ahead of print].
35. Li K., Luo J., Wang C., He H. α-Galactosylceramide potently augments M2e-induced protective immunity against highly pathogenic H5N1 avian influenza virus infection in mice. Vaccine 2011, 29:7711-7717.
36. Rosas G., Fragoso G., Ainciart N., Esquivel-Guadarrama F., Santana A., Bobes R.J., et al. Brucella spp. lumazine synthase: a novel adjuvant and antigen delivery system to effectively induce oral immunity. Microbes Infect 2006, 8(5):1277-1286.
37. Jegerlehner A., Schmitz N., Storni T., Bachmann M.F. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol 2004, 172:5598-5605.
38. Denkers E.Y., Badger C.C., Ledbetter J.A., Bernstein I.D. Influence of antibody isotype on passive serotherapy of lymphoma. J Immunol 1985, 135(3):2183-2186.
39. Israeli E., Agmon-Levin N., Blank M., Shoenfeld Y. Adjuvants and autoimmunity. Lupus 2009, 18(13):1217-1225.